Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Acquired Immunodeficiency Syndrome

ClinicalTrials.gov lists 3,027 trials for Acquired Immunodeficiency Syndrome or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 310.

MeSH D000163 Infections C01 C12 C20
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 459 Phase 1/2 Phase 1/2 66 Phase 2 Phase 2 320 Phase 2/3 Phase 2/3 29 Phase 3 Phase 3 239 Phase 4 Phase 4 211 Not applicable Not applicable 1,165 Observational Observational 532 Phase 1 Phase 1 459 Phase 1/2 Phase 1/2 66 Phase 2 Phase 2 320 Phase 2/3 Phase 2/3 29 Phase 3 Phase 3 239 Phase 4 Phase 4 211 Not applicable Not applicable 1,165 Observational Observational 532

Trials per phase (log scale)

1 more section with rows

3,027 of the 3,027 trials are tagged with Acquired Immunodeficiency Syndrome itself; the rest are tagged with a narrower condition beneath it.

Get the Acquired Immunodeficiency Syndrome report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Acquired Immunodeficiency Syndrome trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 12 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 158

1990: 4 trials (Observational 1, Phase 3 1, Phase 2 2) 1991: 1 trials (Phase 3 1) 1992: 8 trials (Observational 5, Not applicable 1, Phase 3 2) 1993: 2 trials (Observational 1, Phase 2 1) 1994: 12 trials (Observational 5, Not applicable 3, Phase 4 2, Phase 1 2) 1995: 5 trials (Observational 1, Not applicable 1, Phase 2 2, Phase 1 1) 1996: 9 trials (Observational 5, Phase 4 1, Phase 2 1, Phase 1 2) 1997: 9 trials (Observational 3, Not applicable 1, Phase 3 1, Phase 2 1, Phase 1/2 1, Phase 1 2) 1998: 5 trials (Observational 3, Phase 2 1, Phase 1 1) 1999: 7 trials (Observational 2, Not applicable 1, Phase 3 2, Phase 1 2) 2000: 11 trials (Observational 7, Not applicable 1, Phase 4 1, Phase 1 2) 2001: 15 trials (Observational 6, Not applicable 3, Phase 3 3, Phase 2 3) 2002: 31 trials (Observational 6, Not applicable 5, Phase 4 6, Phase 3 6, Phase 2/3 1, Phase 2 7) 2003: 29 trials (Observational 10, Not applicable 3, Phase 4 5, Phase 3 4, Phase 2 4, Phase 1/2 2, Phase 1 1) 2004: 47 trials (Observational 11, Not applicable 10, Phase 4 9, Phase 3 10, Phase 2/3 1, Phase 2 5, Phase 1 1) 2005: 59 trials (Observational 15, Not applicable 9, Phase 4 9, Phase 3 5, Phase 2 16, Phase 1/2 1, Phase 1 4) 2006: 64 trials (Observational 11, Not applicable 8, Phase 4 9, Phase 3 10, Phase 2/3 1, Phase 2 14, Phase 1/2 3, Phase 1 8) 2007: 76 trials (Observational 14, Not applicable 15, Phase 4 10, Phase 3 11, Phase 2/3 4, Phase 2 14, Phase 1/2 2, Phase 1 6) 2008: 88 trials (Observational 20, Not applicable 19, Phase 4 15, Phase 3 8, Phase 2/3 1, Phase 2 10, Phase 1/2 2, Phase 1 13) 2009: 101 trials (Observational 21, Not applicable 20, Phase 4 12, Phase 3 7, Phase 2/3 1, Phase 2 20, Phase 1/2 4, Phase 1 16) 2010: 88 trials (Observational 17, Not applicable 15, Phase 4 9, Phase 3 10, Phase 2 11, Phase 1/2 3, Phase 1 23) 2011: 104 trials (Observational 24, Not applicable 24, Phase 4 12, Phase 3 15, Phase 2/3 1, Phase 2 7, Phase 1/2 4, Phase 1 17) 2012: 85 trials (Other 1, Observational 21, Not applicable 31, Phase 4 3, Phase 3 7, Phase 2/3 3, Phase 2 6, Phase 1/2 2, Phase 1 11) 2013: 95 trials (Observational 18, Not applicable 39, Phase 4 6, Phase 3 7, Phase 2/3 4, Phase 2 7, Phase 1/2 5, Phase 1 9) 2014: 104 trials (Observational 20, Not applicable 30, Phase 4 4, Phase 3 9, Phase 2/3 2, Phase 2 12, Phase 1/2 5, Phase 1 22) 2015: 118 trials (Observational 23, Not applicable 44, Phase 4 9, Phase 3 7, Phase 2/3 1, Phase 2 7, Phase 1/2 4, Phase 1 23) 2016: 114 trials (Observational 16, Not applicable 48, Phase 4 9, Phase 3 11, Phase 2/3 2, Phase 2 3, Phase 1/2 3, Phase 1 22) 2017: 149 trials (Observational 29, Not applicable 77, Phase 4 11, Phase 3 3, Phase 2 10, Phase 1/2 1, Phase 1 18) 2018: 139 trials (Observational 25, Not applicable 78, Phase 4 8, Phase 3 5, Phase 2/3 1, Phase 2 5, Phase 1/2 3, Phase 1 14) 2019: 158 trials (Observational 37, Not applicable 84, Phase 4 8, Phase 3 3, Phase 2/3 1, Phase 2 7, Phase 1/2 2, Phase 1 16) 2020: 118 trials (Observational 24, Not applicable 58, Phase 4 10, Phase 3 3, Phase 2/3 2, Phase 2 8, Phase 1/2 3, Phase 1 10) 2021: 125 trials (Observational 23, Not applicable 62, Phase 4 14, Phase 3 3, Phase 2 10, Phase 1/2 2, Phase 1 11) 2022: 108 trials (Observational 22, Not applicable 58, Phase 4 5, Phase 3 3, Phase 2/3 1, Phase 2 4, Phase 1/2 2, Phase 1 13) 2023: 112 trials (Observational 19, Not applicable 62, Phase 4 8, Phase 3 4, Phase 2 5, Phase 1/2 3, Phase 1 11) 2024: 88 trials (Observational 16, Not applicable 48, Phase 4 2, Phase 3 4, Phase 2 7, Phase 1/2 4, Phase 1 7) 2025: 76 trials (Observational 13, Not applicable 43, Phase 4 4, Phase 3 4, Phase 2/3 2, Phase 2 5, Phase 1/2 2, Phase 1 3)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 90
2025 76
2024 88
2023 112
2022 108
2021 125
2020 118
2019 158
2018 139
2017 149

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 110 trials starting in 2026 and about 87 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 184 trials still running at the 2026-10-09 snapshot; registered median of 24 months across 1,754 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Acquired Immunodeficiency Syndrome trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 459
Phase 1/2 66
Phase 2 320
Phase 2/3 29
Phase 3 239
Phase 4 211
Not applicable 1,165
Observational 532
Expanded access 6

How many Acquired Immunodeficiency Syndrome trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 75
Recruiting 168
Enrolling by invitation 18
Active, not recruiting 77
Available 2

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Acquired Immunodeficiency Syndrome trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 310
ViiV Healthcare 150
Merck Sharp & Dohme LLC 36
Gilead Sciences 35
National Cancer Institute (NCI) 33

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Acquired Immunodeficiency Syndrome? (10)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Zidovudine 141
LAMIVUDINE 41
Ganciclovir 32
Zalcitabine 31
Efavirenz 29

Showing 5 of 10 drugs.

Start your 14-day trial Email me all 10 drugs as a PDF

Interventions as named in the registry (5)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Dolutegravir Pill 62
Ritonavir (RTV) low 45
didanosine, ddI (drug) 42
Fluconazol 32
Nevirapine IR 21

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Acquired Immunodeficiency Syndrome trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Malaria 408 10
Pneumonia 397 72
Neutropenia 164 17
Death 148 31
Cellulitis 128 50

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Acquired Immunodeficiency Syndrome? (1,190)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
The Impact of an Economic Empowerment Intervention on Economic Security among AIDS-Orphaned Adolescents in Southern Uganda: the Moderating Role of Depression. AIDS and behavior 2026 Yes
Coronary artery calcium and all-cause mortality in the Multicenter AIDS Cohort Study. Atherosclerosis 2025 Yes
Multiple-family group intervention programming to improve mental health of adolescents living with HIV/AIDS in Ghana: An implementation science study protocol. PloS one 2025 Yes
Single high-dose liposomal amphotericin B plus B/F/TAF for AIDS-associated talaromycosis in China: a multicentre randomised controlled trial protocol. BMJ open 2025 Yes
The Association of HIV-Specific Risk Factors with Cardiovascular Events in Addition to Traditional Risk Factors in People Living with HIV. AIDS research and human retroviruses 2024 Yes

Showing 5 of 1,190 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Rare acquired immunodeficiency 310050 Exact Orphanet Rare Disease Ontology (ORDO)
Rare acquired immunodeficiency 310050 Exact Orphadata Science knowledge files, Product 1

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and sub-conditions in mesh.

Browse all condition evidence pages